Without the On-CARlytics patient protection, the product would not be seen as a valuable asset.
I see this as Imugene Management showing some confidence moving forward.
With the amount of time, resource and funds that go into obtaining a patient is an immense project within itself.
If anybody on the forum has tried & succeeded in obtaining a patient, you will know what i mean.
It's just not worth the expense unless you have some confidence with what you're looking to achieve.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
26.5¢ |
Change
-0.010(3.64%) |
Mkt cap ! $76.45M | |||
| Open | High | Low | Value | Volume |
| 27.0¢ | 27.5¢ | 26.0¢ | $429.4K | 1.618M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 17 | 433247 | 26.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.5¢ | 28052 | 5 |
View Market Depth
| Last trade - 16.10pm 08/08/2025 (20 minute delay) ? |
| IMU (ASX) Chart |